Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and United Kingdom.
CONCLUSIONS: Results indicate that physicians are prescribing PCSK9i to patients with high cardiovascular risk in accordance with European guidelines and reimbursement requirements.
PMID: 30289004 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Germany Health | Heart | Heart Attack | Research | Spain Health | Statin Therapy | Study | UK Health | Vytorin | Zetia